Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
30 mai 2023 09h00 HE
|
Silo Pharma, Inc.
Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissue ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Brain Health Supplements Market (Product, Dosage Form) - Reach $14.24Bn by 2028 at 11.7% CAGR with Natural Molecules Segment Driving Growth During 2022–2028 | The Insight Partners
30 mai 2023 07h33 HE
|
The Insight Partners
New York, May 30, 2023 (GLOBE NEWSWIRE) -- The Insight Partners published latest research report on "Brain Health Supplements Market Size Report, Share, Growth, Scope & Demand Forecast to 2028 -...
Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
30 mai 2023 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company...
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors
29 mai 2023 19h42 HE
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the...
PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA
16 mai 2023 11h37 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing...
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
01 mai 2023 18h52 HE
|
PharmAla Biotech
CORTEXA TO BE THE LEADING SUPPLIER OF MDMA AND PSILOCYBIN IN AUSTRALIA VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is...
Quarterly Activities and Cashflow Report
28 avr. 2023 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel,...
Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
27 avr. 2023 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, April 27, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel allosteric ion...
Silo Pharma to Present at Psychedelic Drug Development Conference
24 avr. 2023 08h15 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional...
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
19 avr. 2023 09h00 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, April 19, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...